- About Us
- Cell Therapy
- Animal Medicine
- Products & Services
- IR/PR
- Contact Us
Canine Immune Cell Therapy
Development of therapeutic immunotherapy for dogs with cancer
Due to the increase in one- and two-person households, low birth rate, and aging population, the number of companion animals is continuously increasing. As a result of increased household incomes, increased attention to companion animals, and increased number of veterinary clinics, the life expectancy of companion animals has increased significantly and various types of cancer have become the leading cause of death in companion dogs.
Pharos Vaccine is cooperating with the Seoul National University Veterinary Medical Teaching Hospital and others and applied human immunotherapy technology to develop cancer immunotherapies including immune cell therapies and immune checkpoint inhibitors for dogs with cancer.
Development Stages
Development of immunogen
Development of formulations
Efficacy and safety test
Clinical trial
Registration
Launching
Porcine Epidemic Diarrhea(PED) Vaccine
Diarrhea is a common disorder in pigs, especially in suckling piglets, which may cause the destruction or weakening of digestive functions of the pig, leading to death. This may result in productivity decline of the pig farm and influence profitability. One of the most important pathogens that cause this, the porcine epidemic diarrhea virus (PEDV), is highly contagious with high fatality rates, and should be managed effectively in pig farms.
The vaccines currently used to prevent porcine epidemic diarrhea (PED) are inactivated and live viral vaccines that use virus, but available PED vaccines have low immunogenicity and require multiple inoculations. Also, there is a discrepancy between the virus in the outbreak and the virus used in the vaccine, which leads to issues in prevention. Furthermore, because PEDV is difficult to culture, there are difficulties in developing vaccines using new viruses.
Pharos Vaccine is developing vaccines that can efficiently correspond to PEDV excluding the virus by the protein engineering platform technology to develop chimeric recombinant proteins as immunogens.
Guinea Pig Efficacy Test Results
Development Stages
Development of immunogen
Development of formulations
Efficacy and safety test
Clinical trial (field)
Approval
Launching
PharoIC
PharoIC® is an immunological agent containing prepared antibacterial and antiviral antibodies and various nutritional supplements to prevent and treat various diseases, including the easily contracted diarrhea in suckling and weaned piglets. The antibody contents of PharoIC® complement the lacking maternal antibodies in the piglet, and various nutritional supplements promote growth. If administered to a piglet within 24 hours after birth, various antibodies included in PharoIC are well absorbed through the intestinal tract, and act as circulating antibodies that have outstanding diarrhea prevention effects through passive immunity. Also, various antibodies of PharoIC® function as maternal antibodies in the intestinal tract of the piglet, which reduce diarrhea caused by gastrointestinal infections by pathogenic viruses.
Target Diseases
Diarrhea due to PED virus, TEG virus, Rotavirus, Pathogenic virus (E.coli), Salmonellosis (Salmonella Typhimu -rium)
Circovirus infection (PCV2), Streptococcusis (Streptococcus Suis), Glasser’s disease (Haemophilus Parasuis), Pasteurella pneumonia (Pasteurella Multocida), Enzootic pneumonia (Mycoplasma Hyopneumoniae), etc.
Development Stages
Development of immunogen
Development of formulations
Efficacy and safety test
Clinical trial (field)
Registration
Launching
